BioMedTracker, a product of Sagient Research Systems, the leading provider of competitive intelligence and investment analytics on the biotech/pharmaceutical sector, today announced the recent launch of its new service, Thought Leader Opinions (TLO). This service provides its subscribers with direct access to the latest expert opinions in the disease areas that they follow within the intuitive BioMedTracker drug information platform. The service provides its subscribers with over 700 recent interviews from:
- 300 medical/clinical Thought Leaders
- 30 Practice Specialties
- 90 Indications
These interviews provide in-depth analysis on the following issues which are crucial to understanding the competitive landscape within a given pharmaceutical market:
- Whether a late stage drug will be approved by the FDA and/or EMA.
- Whether that drug's approval will affect current prescription practice.
- What market implications the recent results of a key trial will have.
- What mechanisms of action and targets show promise for earlier stage drugs in a particular indication.
- How recent safety concerns will affect how a doctor prescribes a particular drug or class of drugs.
- How the pricing of a new medicine will impact its uptake in the market
"With increasing volatility surrounding FDA Advisory Panel decisions in recent months, understanding what experts think about drugs in development before they reach the advisory panel has never been more important," said Robert Kyle, CEO of Sagient Research. "We launched the Thought Leader Opinion service to give our customers unparalleled access to this predictive information within the easy-to-use BioMedTracker drug database platform to help them better predict the approvability and future market potential of the drugs that they follow."
In conjunction with the launch of the Thought Leader Opinion Service, BioMedTracker is currently offering limited free trials.
CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies